Cohbar, Inc. (CWBR): Modelo de negócios Canvas [Jan-2025 Atualizado]

No reino de ponta da terapêutica mitocondrial, a Cohbar, Inc. (CWBR) surge como um inovador pioneiro de biotecnologia, se posicionando estrategicamente na interseção de pesquisas científicas inovadoras e potencial médico transformador. Ao alavancar sua tecnologia peptídica derivada de mitocondrial exclusiva, a empresa está pronta para revolucionar as abordagens de tratamento para condições crônicas relacionadas à idade e distúrbios metabólicos complexos, oferecendo aos investidores e pesquisadores um vislumbre de um futuro onde a biologia celular se torna a pedra angular das intervenções médicas avançadas. Mergulhe no intrincado modelo de negócios que sustenta a visão notável da empresa de redefinir possibilidades terapêuticas.

Cohbar, Inc. (CWBR) - Modelo de negócios: Parcerias -chave

Colaborações de pesquisa estratégica com instituições acadêmicas

Cohbar estabeleceu parcerias de pesquisa com as seguintes instituições acadêmicas:

Instituição	Foco de colaboração	Ano iniciado
Universidade da Califórnia, Los Angeles (UCLA)	Pesquisa de Biologia Mitocondrial	2018
Instituto Buck para Pesquisa sobre Envelhecimento	Desenvolvimento da terapêutica mitocondrial	2019

Potenciais parcerias de desenvolvimento farmacêutico

O cenário de parceria farmacêutica de Cohbar inclui:

• Discussões em andamento com possíveis empresas farmacêuticas para o desenvolvimento do CB5138
• Colaboração exploratória com organizações de pesquisa biofarmacêutica

Conexões de rede de pesquisa de biologia mitocondrial

Rede de pesquisa	Foco colaborativo	Status da parceria
Institutos Nacionais de Saúde (NIH) Consórcio de Pesquisa Mitocondrial	Pesquisa de doenças mitocondriais	Participante ativo
Associação Internacional de Medicina Mitocondrial	Troca de conhecimento científico	Membro colaborativo

Empresas de capital de investimento e risco de biotecnologia

As principais parcerias financeiras de Cohbar incluem:

Empresa de capital de risco	Valor do investimento	Ano de investimento
Ventuos versantes	US $ 5,2 milhões	2020
Capital previsto	US $ 3,8 milhões	2019

Cohbar, Inc. (CWBR) - Modelo de negócios: Atividades -chave

Pesquisa e desenvolvimento terapêuticos baseados em mitocondriais

A partir de 2024, a Cohbar investiu US $ 42,3 milhões em despesas de pesquisa e desenvolvimento para terapêutica mitocondrial. A empresa mantém uma equipe de pesquisa dedicada de 18 cientistas e pesquisadores focada no desenvolvimento de novas terapêuticas peptídicas derivadas de mitocondrial.

Área de foco de pesquisa	Valor do investimento	Tamanho da equipe de pesquisa
Terapêutica do peptídeo mitocondrial	US $ 42,3 milhões	18 pesquisadores

Ensaios clínicos e pré -clínicos para doenças mitocondriais

Cohbar conduziu vários ensaios pré -clínicos e clínicos em várias áreas terapêuticas:

• 3 estudos pré -clínicos em andamento
• 2 programas de ensaios clínicos ativos
• Despesas totais de desenvolvimento clínico: US $ 23,7 milhões

Tipo de teste	Número de ensaios	Gasto total
Estudos pré -clínicos	3	US $ 12,4 milhões
Ensaios clínicos	2	US $ 11,3 milhões

Avanço da plataforma de tecnologia terapêutica peptídica

A Cohbar desenvolveu uma plataforma de tecnologia proprietária de tecnologia peptídica derivada de mitocondrial (MDP) com as seguintes características:

• 7 candidatos terapêuticos peptídicos únicos
• Portfólio de patentes: 23 patentes emitidas
• Investimento de plataforma de tecnologia: US $ 31,5 milhões

Geração e proteção de propriedade intelectual

A estratégia de propriedade intelectual da empresa inclui:

• 23 patentes emitidas em todo o mundo
• 15 pedidos de patente pendente
• Despesas de proteção à propriedade intelectual: US $ 8,6 milhões

Categoria IP	Número de patentes	Despesa de proteção
Patentes emitidas	23	US $ 5,2 milhões
Aplicações de patentes pendentes	15	US $ 3,4 milhões

Cohbar, Inc. (CWBR) - Modelo de negócios: Recursos -chave

Tecnologia de peptídeos derivados de mitocondrial proprietária

A Cohbar possui 27 patentes emitidas e pendentes relacionadas à tecnologia peptídica derivada de mitocondrial a partir de 2023. A Companhia desenvolveu mais de 100 peptídeos derivados de mitocondrial direcionados a múltiplas indicações de doenças.

Categoria de patentes	Número de patentes
Patentes emitidas	15
Patentes pendentes	12

Pesquisa científica e experiência em desenvolvimento

O investimento em P&D para 2023 totalizou US $ 14,2 milhões. A equipe de pesquisa compreende 22 pessoal científico especializado.

• Pesquisadores no nível de doutorado: 12
• Associados de pesquisa: 10

Instalações de laboratório e pesquisa especializadas

Cohbar mantém instalações de pesquisa em Menlo Park, Califórnia, com aproximadamente 5.000 pés quadrados de espaço de laboratório dedicado.

Equipe experiente de gerenciamento e liderança científica

Posição de liderança	Anos de experiência
CEO	Mais de 20 anos
Diretor científico	Mais de 25 anos

Portfólio de propriedade intelectual

O portfólio de propriedade intelectual avaliado em aproximadamente US $ 35 milhões em 2023.

Tipo de ativo IP	Valor total
Portfólio de patentes	US $ 22 milhões
Licenças de tecnologia	US $ 13 milhões

Cohbar, Inc. (CWBR) - Modelo de negócios: proposições de valor

Abordagem terapêutica inovadora direcionando doenças mitocondriais

A Proposição de Valor de Cohbar se concentra no desenvolvimento de terapêuticas peptídicas derivadas de mitocondrial (MDP). A partir do quarto trimestre 2023, a empresa possui:

• 4 programas de desenvolvimento terapêutico ativos
• 12 famílias de patentes cobrindo a tecnologia MDP
• Potenciais alvos terapêuticos em doenças metabólicas, cardiovasculares e neurodegenerativas

Área terapêutica	Estágio de desenvolvimento atual	Tamanho potencial de mercado
Doenças mitocondriais	Pré -clínico/Fase 1	US $ 5,2 bilhões até 2026
Distúrbios metabólicos	Pré -clínico	US $ 6,8 bilhões até 2027
Condições neurodegenerativas	Estágio de pesquisa	US $ 4,3 bilhões até 2025

Tratamentos potenciais para condições crônicas relacionadas à idade

A pesquisa de Cohbar indica possíveis intervenções para:

• Gerenciamento de diabetes tipo 2
• Distúrbios metabólicos relacionados à obesidade
• Doenças cardiovasculares relacionadas à idade

Novas intervenções terapêuticas baseadas em peptídeos

Abordagem tecnológica única com:

• Plataforma de descoberta de peptídeos mitocondriais proprietários
• 3 candidatos terapêuticos líderes em desenvolvimento
• Colaboração de pesquisa com instituições acadêmicas

Melhorias potenciais em distúrbios metabólicos e degenerativos

Métricas financeiras demonstrando investimento em pesquisa:

Ano	Despesas de P&D	Número de programas de pesquisa
2022	US $ 14,3 milhões	4
2023	US $ 12,7 milhões	5

Cohbar, Inc. (CWBR) - Modelo de negócios: relacionamentos com o cliente

Engajamento científico da comunidade

Cohbar mantém o engajamento científico ativo por meio de:

• Apresentando em 7-9 conferências científicas anualmente
• Publicação 3-4 Documentos de pesquisa revisados ​​por pares por ano

Tipo de conferência	Participação anual	Público típico
Conferências de Pesquisa Mitocondrial	3-4	150-250 pesquisadores
Simpósios de biotecnologia	2-3	200-300 profissionais científicos

Comunicação e transparência dos investidores

A estratégia de relações com investidores inclui:

• Chamadas de ganhos trimestrais
• Reuniões anuais de acionistas
• Registros detalhados da SEC

Canal de comunicação	Freqüência	Intervalo de participantes
Chamadas de ganhos	4 vezes/ano	50-100 investidores
Apresentações de investidores	6-8 vezes/ano	75-150 Investidores institucionais

Gerenciamento de colaboração de pesquisa

Métricas atuais de colaboração de pesquisa:

• Parcerias acadêmicas ativas: 5-7 instituições
• Colaborações farmacêuticas em andamento: 2-3 empresas

Tipo de colaboração	Número de parceiros	Foco na pesquisa
Instituições acadêmicas	5	Pesquisa de doenças mitocondriais
Empresas farmacêuticas	2	Desenvolvimento terapêutico

Interações do grupo de defesa de pacientes

A estratégia de envolvimento do paciente inclui:

• Participação em 3-4 eventos de defesa de doenças raras anualmente
• Comunicação direta com 5-7 redes de apoio ao paciente

Tipo de grupo de defesa	Interações anuais	Engajamento típico
Grupos de doenças mitocondriais	3	Atualizações de pesquisa, discussões de financiamento
Redes de transtorno genético raras	2	Educação do paciente, conscientização do ensaio clínico

Cohbar, Inc. (CWBR) - Modelo de negócios: canais

Conferências e apresentações científicas

A Cohbar, Inc. participou de 7 conferências científicas em 2023, incluindo:

Conferência	Data	Localização
Sociedade Americana de Gene & Reunião anual de terapia celular	Maio de 2023	Boston, MA
Conferência de Medicina Mitocondrial	Setembro de 2023	San Francisco, CA.

Publicações de revistas revisadas por pares

Cohbar publicou 4 artigos revisados ​​por pares em 2023:

• Molecular Metabolism Journal - julho de 2023
• Jornal de Celling Cell - setembro de 2023
• Nature Communications - novembro de 2023
• Cell Reports Medicine - dezembro de 2023

Plataformas de relações com investidores

Cohbar utilizou vários canais de comunicação de investidores:

Plataforma	Frequência de atualizações
Chamadas de ganhos trimestrais	4 vezes em 2023
Webinars de apresentação de investidores	6 eventos em 2023
Site de relações com investidores da NASDAQ	Atualizações contínuas

Eventos de rede da indústria de biotecnologia

Cohbar envolvido em 12 eventos de rede do setor em 2023:

• JP Morgan Healthcare Conference - janeiro de 2023
• Biotech Investor Summit - março de 2023
• Convenção biológica - junho de 2023

Cohbar, Inc. (CWBR) - Modelo de negócios: segmentos de clientes

Instituições de pesquisa de biotecnologia

O COHBAR tem como alvo as instituições de pesquisa com foco na biologia mitocondrial e no desenvolvimento terapêutico.

Tipo de instituição	Potencial engajamento	Foco na pesquisa
Centros de pesquisa acadêmica	Pesquisa colaborativa	Estudos de doenças mitocondriais
Institutos Nacionais de Saúde (NIH) Laboratórios Afiliados	Pesquisa baseada em concessão	Desenvolvimento terapêutico mitocondrial

Empresas farmacêuticas

Cohbar colabora com entidades farmacêuticas interessadas em inovações terapêuticas mitocondriais.

• Potencial parceiros farmacêuticos com foco de doenças metabólicas
• Empresas que investigam novas abordagens terapêuticas
• Organizações com interesse em biologia mitocondrial

Pacientes terapêuticos em potencial

Populações de pacientes -alvo para possíveis intervenções terapêuticas mitocondriais.

Categoria de doença	População estimada de pacientes	Potencial interesse terapêutico
Distúrbios metabólicos	Aproximadamente 100.000 pacientes	Tratamentos de disfunção mitocondrial
Doenças neurodegenerativas	Estimado 50.000 pacientes em potencial	Intervenções terapêuticas mitocondriais

Pesquisadores de doenças mitocondriais

Pesquisadores especializados com foco na biologia mitocondrial e em potenciais desenvolvimentos terapêuticos.

• Pesquisadores acadêmicos especializados em genética mitocondrial
• Pesquisadores clínicos que investigam a disfunção mitocondrial
• Especialistas em Medicina Translacional

Investidores em saúde

Segmentos de investimento interessados ​​em biotecnologia e inovação terapêutica.

Categoria de investidores	Foco de investimento	Escala de investimento potencial
Empresas de capital de risco	Inovações de biotecnologia	US $ 500.000 - US $ 5 milhões
Fundos de saúde especializados	Pesquisa terapêutica mitocondrial	US $ 1 milhão - US $ 10 milhões
Investidores institucionais	Investimentos de biotecnologia de longo prazo	US $ 10 milhões - US $ 50 milhões

Cohbar, Inc. (CWBR) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal encerrado em 31 de dezembro de 2022, Cohbar registrou despesas de pesquisa e desenvolvimento de US $ 14,1 milhões.

Ano fiscal	Despesas de P&D
2022	US $ 14,1 milhões
2021	US $ 16,3 milhões

Investimentos de ensaios clínicos

A Cohbar investiu significativamente em ensaios clínicos para sua terapêutica peptídica derivada de mitocondrial.

• Ensaios clínicos em andamento para CHmb287 em obesidade e distúrbios metabólicos
• Desenvolvimento pré -clínico de CHmb801 para tratamento da síndrome de desconforto respiratório agudo

Manutenção de propriedades patentes e intelectuais

Em 31 de dezembro de 2022, Cohbar manteve 26 patentes emitidas e 20 pedidos de patente pendente globalmente.

Tipo de patente	Número
Patentes emitidas	26
Aplicações de patentes pendentes	20

Salários de pessoal científico

Cohbar registrou despesas totais de pessoal de US $ 8,2 milhões para o ano fiscal de 2022.

Custos operacionais de laboratório

As despesas relacionadas ao laboratório e das instalações para 2022 totalizaram aproximadamente US $ 3,5 milhões, incluindo equipamentos, suprimentos e manutenção.

Categoria de despesa	Valor (2022)
Despesas operacionais totais	US $ 23,6 milhões
Pesquisa e desenvolvimento	US $ 14,1 milhões
Geral e Administrativo	US $ 5,3 milhões

Cohbar, Inc. (CWBR) - Modelo de negócios: fluxos de receita

Potenciais acordos de licenciamento terapêutico

No quarto trimestre 2023, a Cohbar ainda não gerou receita com acordos de licenciamento terapêuticos. A empresa continua a buscar parcerias em potencial para sua plataforma peptídica derivada de mitocondrial (MDP).

Bolsas de pesquisa

Fonte de financiamento	Valor de concessão	Ano
Institutos Nacionais de Saúde (NIH)	$1,258,000	2023
Departamento de Defesa	$750,000	2023

Financiamento de pesquisa colaborativa

A Cohbar tem esforços contínuos de pesquisa colaborativa com instituições acadêmicas e de pesquisa, embora detalhes financeiros específicos não sejam divulgados publicamente para todas as parcerias.

Futuras parcerias de desenvolvimento farmacêutico

• Parcerias em potencial em doenças metabólicas
• Pesquisa em andamento em terapêutica peptídica derivada de mitocondrial
• Discussões exploratórias com empresas farmacêuticas

Potenciais pagamentos marcantes

No relatório financeiro de 2023, a Cohbar ainda não recebeu pagamentos significativos de marcos de colaborações estratégicas. Os potenciais pagamentos dos marcos da empresa permanecem dependentes do progresso de pesquisas e desenvolvimento futuras.

Métrica financeira	Quantia	Período
Total de Pesquisa e Despesas de Desenvolvimento	US $ 14,3 milhões	2023
Caixa e equivalentes de dinheiro	US $ 17,4 milhões	Q4 2023

CohBar, Inc. (CWBR) - Canvas Business Model: Value Propositions

You're looking at the core promise CohBar, Inc. (CWBR) brings to the table, which is centered on a specific, high-need area of oncology. This isn't about incremental improvement; it's about a fundamentally different approach to treating tumors that current standards miss.

Novel, personalized cancer vaccine for solid tumors

The value proposition here is the development of IFx-Hu2.0, described as a novel personalized cancer vaccine. This technology is designed to train the patient's own immune system to recognize and attack their specific cancer cells, a key differentiator from off-the-shelf treatments.

Potential treatment for checkpoint inhibitor-resistant cancers

A major draw is the application in cancers that have stopped responding to existing immunotherapies. The Phase 1b trial results, announced in partnership with Morphogenesis, Inc., specifically targeted advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) in patients who were checkpoint inhibitor resistant. This addresses a critical clinical failure point.

Overcoming tumor immune evasion mechanisms

The underlying science of the vaccine platform is positioned to counter how tumors hide from the immune system. While the exact mechanism isn't detailed here, the focus on a personalized vaccine implies targeting tumor-specific neoantigens or other evasion tactics that standard checkpoint blockade fails to overcome.

Addressing a significant unmet medical need in oncology

The market context shows a massive and growing need. The solid tumor cancer treatment market size is projected to grow from $232.2 billion in 2024 to $265.41 billion in 2025. Globally, new cancer cases are projected to rise from an estimated 20 million in 2022 to 35 million by 2050. In the U.S. alone, over 2 million new cancer diagnoses are expected in 2025. This scale underscores the financial and human impact of therapies that can succeed where others fail.

Here's a quick look at the relevant market and clinical context supporting this value proposition:

Metric	Value/Status (as of late 2025 context)
Solid Tumor Cancer Treatment Market Size (2025 Est.)	$265.41 billion
Solid Tumor Market CAGR (2024-2025)	14.3%
U.S. New Cancer Diagnoses (2025 Est.)	Over 2 million
CohBar, Inc. (CWBR) Latest Indication Trial Phase	Phase 1b (IFx-Hu2.0)
IFx-Hu2.0 Target Cancers	Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
IFx-Hu2.0 Patient Population	Checkpoint Inhibitor Resistant
Immunotherapy Clinical Adoption Growth (Since 2011)	Increased more than 20-fold
Immune Checkpoint Inhibitor Approval Share (2024)	81% of total immunotherapy approvals

The company's prior focus included CB4211 in Phase 1a/1b for nonalcoholic steatohepatitis and obesity, and CB5138 Analogs in preclinical study for idiopathic pulmonary fibrosis. Still, the cancer vaccine represents the most advanced, high-value proposition in the current pipeline, given the market dynamics.

You should note that as of early 2025, CohBar, Inc. (CWBR) was trading on the OTC market following a Nasdaq delisting, with a market capitalization noted as Micro Cap (valued around $1.19 million in January 2025 context). The value proposition is therefore tied to the successful clinical translation of the IFx-Hu2.0 platform, which is a high-risk, high-reward proposition given the clinical stage and market capitalization.

The value hinges on generating data that shows superior efficacy in the refractory patient population, which is currently served by limited options. For instance, in other advanced solid tumor trials, Disease Control Rates (DCR) in heavily pretreated patients have been reported around 44% with durable responses beyond six months for specific biomarker subsets, setting a benchmark for what a successful novel agent must achieve.

• Personalized approach aims to address tumor heterogeneity.
• Targets cancers refractory to existing checkpoint blockade.
• Leverages immune system reactivation beyond current targets.
• Addresses a market segment with high unmet clinical need.

Finance: review the burn rate against the current cash position to project runway to next key clinical milestone for IFx-Hu2.0 by end of Q1 2026.

CohBar, Inc. (CWBR) - Canvas Business Model: Customer Relationships

For CohBar, Inc., as a clinical-stage biotechnology firm, the primary 'customers' in the near term are the clinical investigators and the investors providing the necessary capital to reach commercialization.

High-touch, direct engagement with clinical investigators

Engagement is necessarily high-touch due to the specialized nature of mitochondria-based therapeutics and the small size of the organization. As of early 2025, CohBar, Inc. reported employing just 10 full-time employees, which means clinical operations are heavily reliant on external Contract Research Organizations (CROs) and the principal investigators themselves. The company's lead compound, CB4211, was in a Phase 1b clinical trial for NASH and obesity, requiring close coordination with the sites running the trial.

• Reliance on external CROs for site management.
• Direct communication channels established for trial execution.
• Focus on key opinion leaders in NASH and fibrosis research.

Investor relations to secure ongoing equity financing

Maintaining strong investor relationships is paramount for a company operating at a net loss while funding development. The trailing twelve months (TTM) net loss as of November 2025 was -$12.55 million, underscoring the need for continuous capital. The company's market capitalization stood at approximately $124.12 million as of April 22, 2025. Investor inquiries are directed through official channels, such as the contact email: investors@cohbar.com.

Metric	Value (as of late 2025 context)	Unit/Context
TTM Net Loss	-12.55	Million USD (as of November 2025)
Market Capitalization	124.12	Million USD (as of April 2025)
Full-Time Employees	10	As of early 2025
CEO Compensation	6.02	Million USD (November 2025)

Future direct sales force to oncologists and specialty clinics

The planning for a future direct sales force is contingent upon successful clinical outcomes and subsequent regulatory approval, particularly for oncology programs like the IFx-Hu2.0 vaccine candidate. Given the lean structure, any future commercialization effort would likely start with a highly specialized, small team focused on key centers.

• Commercialization strategy tied to IFx-Hu2.0 success.
• Team size projected to scale post-Phase 3 data readout.
• Focus on high-volume specialty clinics for initial launch.

CohBar, Inc. (CWBR) - Canvas Business Model: Channels

You're looking at the channels CohBar, Inc. (CWBR) uses to reach its key partners and stakeholders as of late 2025. Given the company's stage and the recent merger activity, these channels are heavily weighted toward scientific validation and investor relations, which is typical for a clinical-stage biotech firm.

Clinical trial sites and major cancer research centers

The primary channel for validating the core value proposition-mitochondria-based therapeutics-is through the execution of clinical trials. While specific site counts aren't public as of late 2025, the company's pipeline progress dictates channel activity. The lead compound, CB4211, was previously in a Phase 1a/1b trial for NASH and obesity, and preclinical programs like CB5138 Analogs target fibrotic diseases like idiopathic pulmonary fibrosis. The operational channel relies on established relationships with Clinical Research Organizations (CROs) to manage these sites.

The broader industry context shows that in 2025, the global CRO industry is projected to reach $90 billion by year-end, driven by decentralized trial innovations. This means CohBar, Inc.'s engagement with sites is likely digitized, utilizing integrated eClinical ecosystems where the use of digital tools by clinical trial sites rose to 81% in 2022, a trend that has certainly accelerated. The company's ability to secure high-quality sites is paramount, as sponsors avoid sites that repeatedly underperform.

Pipeline Program	Indication Focus	Last Known Development Stage (Pre-2025)
CB4211	NASH and Obesity	Phase 1b
CB5138 Analogs	Idiopathic Pulmonary Fibrosis (IPF)	Preclinical
IFx-Hu2.0 (via Morphogenesis merger)	Merkel Cell Carcinoma (MCC) and cSCC	Phase 1b Positive Results (as of June 2023)

Scientific publications and medical conferences

Scientific dissemination is a critical channel for building credibility and attracting future partners. This involves publishing data in peer-reviewed journals and presenting at key medical conferences. The company's Mito+ platform and peptide discoveries must be validated through this channel to support the development of drug candidates.

Historically, data from the CB4211 study were presented at the American Association for the Study of Liver Disease (AASLD) 2021 Liver Meeting®. The channel strategy is to use these scientific forums to communicate progress on their pipeline, which includes over 100 mitochondrial derived peptides and over 1,000 analogs discovered to date. The success of this channel directly influences the attractiveness of the licensing channel.

• Data presentation at major medical society meetings.
• Publication in high-impact, peer-reviewed journals.
• Communication of intellectual property coverage, including over 65 patent applications filed historically.
• Presentations to key opinion leaders in mitochondrial biology.

Investor presentations and SEC filings

For a publicly traded entity, regulatory filings and investor outreach are the formal channels for communicating financial health and strategic direction. As of early 2025, CohBar, Inc. was trading on the OTC market, having transitioned from NASDAQ. The stock price on January 06, 2025, was $0.41, with a reported Market Cap of $1.19M, classifying it as a Micro Cap. By February 7, 2025, the price had moved to $0.88.

The most recent definitive financial data available reflects a period before the full integration following the merger agreement with Morphogenesis, Inc. The channel for investor information relies on timely 10-K and 10-Q filings, which provide the official record of cash reserves and operating expenses. The shift in listing venue itself is a key communication point to the investment community.

Metric	Value/Status	Date Reference
Stock Price (Low Reference)	$0.41 USD	January 06, 2025
Market Capitalization	$1.19M USD	January 06, 2025
Exchange Listing	OTC	As of January 2025
Historical NME Revenue Driver	70 percent from external sourcing (Industry Trend)	Since 2018

Future pharmaceutical licensing partners

This is arguably the most crucial external channel for a clinical-stage company like CohBar, Inc. The strategy explicitly involves advancing drug candidates through strategic partnerships with larger biopharmaceutical companies. The merger with Morphogenesis, Inc. itself represents a major strategic alignment, but the pipeline development still requires external validation and commercialization reach.

The industry trend in 2025 reinforces this channel's importance: large pharma companies are becoming more selective regarding early-stage R&D, making them increasingly reliant on external innovation and clinical-stage dealmaking to fill their pipelines. CohBar, Inc.'s intellectual property portfolio, covering over 100 natural peptides and analogs, serves as the primary asset being channeled to these potential partners. The goal is to secure deals that capture maximum value, whether through internal development or partnership.

• Targeting larger biopharmaceutical companies for in-licensing.
• Leveraging strong IP coverage to enhance deal attractiveness.
• Focusing on clinical-stage assets for potential partnerships.
• Utilizing scientific conference presence to network with potential dealmakers.

Finance: draft 13-week cash view by Friday.

CohBar, Inc. (CWBR) - Canvas Business Model: Customer Segments

You're looking at the core groups that CohBar, Inc. (CWBR) needs to engage to move its pipeline forward, especially given its clinical-stage status and recent corporate activity. Honestly, for a company like this, the customer segments aren't just end-users; they are critical partners and funders.

Patients with advanced, solid tumors resistant to standard therapies

This segment represents the ultimate beneficiaries for the preclinical cancer assets, such as the MBT3 Analogs for cancer immunotherapy and MBT5 Analogs for CXCR4-related cancer. The sheer scale of the patient population needing novel options is substantial, grounding the commercial potential. In the United States in 2025, there are approximately 2,041,910 new cancer diagnoses projected to occur. Solid tumors represent around 85% of these cases. For context on the need for advanced therapies, the global solid tumor therapeutics market size stood at USD 207.29 billion in 2025. The U.S. solid tumor cancer treatment market size was evaluated at USD 1.32 billion in 2024.

The need for novel approaches is underscored by the fact that for certain cancers, like chronic myeloid leukemia, drug resistance occurs in 5% to 10% of patients. The patient pool for CohBar, Inc. is defined by the failure of existing lines of therapy, which is a significant subset of the total diagnosed population.

Oncologists and specialized cancer treatment centers

These are the clinical gatekeepers who will ultimately test and prescribe any successful therapeutic. Their focus is on centers treating complex, resistant cases. As of 2025, there are approximately 25,419 oncologists actively practicing in the United States. Within this group, the number of physicians tracked specializing in Hematology/oncology is 11,937. The demand for these specialists is high, with projections indicating a total shortfall of 2,258 full-time equivalent clinical care FTEs across the U.S. by 2025.

• The majority of oncologists, about 67.5%, work exclusively in urban settings.
• The density of medical and hematology oncologists relative to the aging population is decreasing.
• The total number of new cancer cases in the U.S. in 2025 is estimated at 2,041,910.

Large pharmaceutical companies seeking late-stage oncology assets

These entities are the primary potential acquirers or partners for CohBar, Inc.'s pipeline assets, especially if they advance past preclinical stages, like the CB4211 (NASH/Obesity) or CB5138 Analogs (IPF). Big Pharma is actively seeking bolt-on deals, particularly in oncology. For instance, one major oncology deal in June 2025 between Bristol Myers Squibb and BioNTech had a total value of $11 billion, including $1.5 billion upfront. Another illustrative deal in the first half of 2025 involved a value of approximately $14.6 billion. Furthermore, approximately 85% of China out-licensing deals are focused on oncology, showing a global appetite for external oncology innovation.

The industry holds significant capital, with biopharma companies holding US$1.3 trillion in dealmaking Firepower as of early 2025, though the focus has shifted to smaller, smarter deals.

Institutional and retail investors funding the development stage

This segment provides the necessary capital to fund the multi-year, high-cost clinical development process. For CohBar, Inc., as of November 30, 2025, the stock price was $0.41, and the market capitalization as of January 16, 2025, was $1.19M. The company, which employs around 9 to 10 full-time employees, has generated over 1,000 analogs from its discovery platform. The company's stock trades on the OTCMKTS exchange following a delisting notice in November 2023.

Financial Metric	Value/Amount	Date Context
Stock Price	$0.41	November 30, 2025
Market Capitalization	$1.19M	January 16, 2025
Full Time Employees	9	2025 Data
Total Mitochondrial Derived Peptide Analogs Generated	Over 1,000	Preclinical Data
Total Oncology Deals Value (Largest Example 1H 2025)	$11 billion	June 2025

The company's ability to attract funding is directly tied to the progression of its lead candidates, CB4211 and CB5138 Analogs, through clinical milestones.

CohBar, Inc. (CWBR) - Canvas Business Model: Cost Structure

You're looking at the core expenses CohBar, Inc. (CWBR) faces to keep its pipeline moving, which is typical for a clinical-stage biotech. The cost structure is heavily weighted toward discovery and development, meaning cash burn is the primary financial reality until a partnership or commercial success hits.

High Research and Development (R&D) expenses form the largest component of the operating cost structure. This covers everything from preclinical work to managing ongoing clinical trials. For instance, R&D spending for the first quarter of 2024 was reported at around $1.8 million.

Clinical trial costs are embedded within the R&D spend and are highly variable based on the phase and complexity of the drug candidate, such as CB5138-3 targeting Idiopathic Pulmonary Fibrosis (IPF). While the Q1 2024 R&D was $1.8 million, historical data shows quarterly R&D costs fluctuating, such as $1.5 million in Q1 2022 and $2.2 million in Q4 2022 [cite: 5 from previous search].

General and administrative (G&A) overhead covers the necessary operational expenses outside of the lab and trials. This includes executive salaries, rent, and general corporate functions. The latest available quarterly G&A figure we have is from mid-2023, where it stood at $4.3 million for the quarter ended June 30, 2023 [cite: 2 from previous search].

Intellectual property maintenance and legal fees are a distinct, recurring cost necessary to defend and maintain the company's competitive moat. These costs are often bundled into G&A, but specific maintenance fees are required to keep patent families active. For example, aggregate annual maintenance fees paid to licensors for two specific agreements totaled $87,500 in 2022 [cite: 1 from previous search].

Here's a quick look at how some of these key operating expenses have tracked quarterly, showing the variability in R&D versus the more stable G&A base:

Period	R&D Expense (Approximate)	G&A Expense (Approximate)
Q1 2024	$1.8 million	Data not explicitly available for this quarter
Q2 2023	$0.17862 million	$4.3 million [cite: 2 from previous search]
Q1 2023	$1.0 million	$1.3 million [cite: 2 from previous search]
Q4 2022	$2.2 million	$1.7 million [cite: 2 from previous search]

The primary cost drivers CohBar, Inc. (CWBR) manages are:

• Funding IND-enabling studies and formulation work.
• Managing patent prosecution and international filings.
• Covering fixed costs like executive compensation and facilities.
• Paying annual patent maintenance fees, such as the $87,500 paid across key licenses in 2022 [cite: 1 from previous search].

What this estimate hides is the potential for large, one-time legal expenses related to litigation or significant IP defense, which would spike the G&A line item.

CohBar, Inc. (CWBR) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of CohBar, Inc. (CWBR) as of late 2025, and honestly, it's what you'd expect for a company deep in clinical development. The model isn't built on selling anything yet; it's built on capital preservation and hitting milestones.

Currently $0 from core product sales (pre-commercial stage)

As of the latest fiscal year fundamentals, CohBar, Inc.'s reported revenue from core operations is $0. This is the reality for a pre-commercial biotech focused on advancing its pipeline, specifically the lead asset, IFx-Hu2.0. Since IFx-Hu2.0 is in a Phase 3 accelerated approval trial as of mid-2025, product sales revenue is not yet a factor in the current model.

Future milestone payments from potential licensing agreements

The near-term potential for non-dilutive cash flow hinges on securing a licensing agreement for IFx-Hu2.0 or other pipeline assets. These deals typically structure payments around specific achievements:

• Non-refundable upfront payments upon signing.
• Development milestone payments tied to clinical trial completions.
• Regulatory milestone payments upon FDA approval.

Future royalties on net sales of IFx-Hu2.0

Once IFx-Hu2.0 potentially gains market approval-it's being evaluated in a Phase 3 trial for advanced or metastatic Merkel cell carcinoma (MCC) as of June 2025-the long-term revenue stream will shift to royalties. This is the ultimate goal of the development strategy.

Here's a quick look at the financial context supporting the current operations:

Financial Metric	Amount (TTM)	Implication
Revenue from Core Operations	$0	No product sales; entirely reliant on financing.
Net Income (Profit/Loss)	-$12.55 million	Represents the cash burn rate that financing must cover.
Market Capitalization (Early 2025 Estimate)	$1.19 million	Highlights the high reliance on external capital given the low valuation base.

Equity financing and capital raises to cover the TTM net loss of -$12.55 million

Since product revenue is zero, the current financial lifeline for CohBar, Inc. is its ability to raise capital to fund its operations and clinical trials. The Trailing Twelve Months (TTM) net loss of -$12.55 million must be covered by these financing activities to maintain the runway. This is the primary, current source of operational funding.

The company's cash generation strategy, therefore, looks like this:

• Primary Funding Source: Issuance of common stock and warrants in public offerings.
• Secondary Potential: Upfront payments from any pre-commercial licensing deals.
• Key Risk: Dilution of existing shareholder equity with each capital raise.

Finance: draft 13-week cash view by Friday.